Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) Director Timothy A. Springer acquired 50,000 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was bought at an average cost of $28.82 per share, for a total transaction of $1,441,000.00. Following the completion of the transaction, the director now directly owns 3,796,764 shares of the company’s stock, valued at $109,422,738.48. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Tectonic Therapeutic Price Performance
TECX stock traded down $0.82 during mid-day trading on Thursday, hitting $28.58. 368,318 shares of the company were exchanged, compared to its average volume of 34,991. The firm has a market cap of $420.98 million, a P/E ratio of 42.61 and a beta of 2.59. The stock’s fifty day moving average is $18.08. Tectonic Therapeutic has a twelve month low of $12.12 and a twelve month high of $31.31.
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($3.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($1.85). On average, equities research analysts expect that Tectonic Therapeutic will post -4.91 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on Tectonic Therapeutic
Hedge Funds Weigh In On Tectonic Therapeutic
Institutional investors have recently made changes to their positions in the stock. Affinity Asset Advisors LLC bought a new stake in Tectonic Therapeutic in the second quarter valued at $961,000. Farallon Capital Management LLC bought a new position in shares of Tectonic Therapeutic in the second quarter worth $7,099,000. Renaissance Technologies LLC bought a new stake in shares of Tectonic Therapeutic during the second quarter valued at about $1,466,000. Atlas Venture Life Science Advisors LLC bought a new position in Tectonic Therapeutic in the 2nd quarter valued at about $6,233,000. Finally, Acadian Asset Management LLC bought a new position in Tectonic Therapeutic in the 2nd quarter valued at about $1,804,000. 62.63% of the stock is owned by institutional investors.
About Tectonic Therapeutic
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
See Also
- Five stocks we like better than Tectonic Therapeutic
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Buy P&G Now, Before It Sets A New All-Time High
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What Are the FAANG Stocks and Are They Good Investments?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.